COMPASS Pathways plc (CMPS) Deutsche Bank 2026 Healthcare Summit September 17, 2026 11:00 AM EDT
Company Participants
Teri Loxam – Chief Financial Officer
Lori Englebert – Chief Commercial Officer
Steve Levine – Chief Patient Officer
Conference Call Participants
YIfei Huang – Deutsche Bank AG, Research Division
Presentation
YIfei Huang
Deutsche Bank AG, Research Division
Okay. All right. Let’s get started. Good morning, everyone. I’m David Huang. I’m the senior U.S. biotech analyst here at Deutsche Bank. So I’d like to welcome everyone to the second day of our second Annual DB Healthcare Summit. With us here, we have COMPASS Pathways for a fireside chat. So COMPASS is a pioneer in the field of psychedelic medicine with its psilocybin therapy, COMP360, on track to becoming the first classic psychedelic to potentially reach the market in 2027. I’m joined by Lori Englebert, Chief Commercial Officer; Teri Loxam, Chief Financial Officer; and Dr. Steve Levine, Chief Patient Officer. So thanks to you all for joining us. I’ll pass it over to the COMPASS team for some introductory remarks to help level set everyone and for those in the audience who may be less familiar with the COMPASS story before we dive into Q&A.
Teri Loxam
Chief Financial Officer
You want me to start? We’re going to be passing it back and forth throughout today. So thanks for having us, first of all. I really appreciate being here. We’ll likely be providing some forward-looking remarks. So because our lawyers are always interested, check our risk factors. But we are, as David mentioned, in the lead in terms of psychedelics potentially getting to market. We’re in really, really good shape. We’ve completed 2 Phase III trials, both being highly statistically significant, really great results and really incredible profile that Lori can talk more about as to why we feel like COMP360 is so differentiated.
